The result was announced during trading hours today, 13 February 2012.
Meanwhile, the BSE Sensex was up 83.73 points, or 0.47%, to 17,832.42.
On BSE, 2.79 lakh shares were traded in the counter as against an average daily volume of 78,115 shares in the past one quarter.
The stock hit a high of Rs 559.40 and a low of Rs 548 so far during the day. The stock had hit a record high of Rs 565.75 on 6 February 2012. The stock had hit a 52-week low of Rs 404 on 24 February 2011.
The stock had underperformed the market over the past one month until 10 February 2012, gaining 4.89% compared with the Sensex's 9.80% rise. The scrip had. however, outperformed the market in past one quarter, rising 10.10% as against 2.23% rise in the Sensex.
The large-cap drug maker has an equity capital of Rs 103.56 crore. Face value per share is Re 1.
Sun Pharmaceuticals reported an EBITDA (earnings before interest, taxes, depreciation and amortization) margin of 45% in Q3 December 2011.
The company said Indian branded generic sales grew by 17% to Rs 695 crore, excluding third party manufacturing business, in Q3 December 2011 over Q3 December 2010. US finished dosage sales grew by 47% to $208 million in the same period. International formulation sales were reported at Rs $56 million.
Dilip Shanghvi, Chairman and Managing Director of Sun Pharmaceuticals Industries, said, Business performance is in line with our expectations and the underlying market growth. We expect the momentum to continue.
The company launched 6 key products during the quarter, taking the total to 20 for the first nine months.
Sun Pharma said it held 4.5% share in the Rs 60,000 crore Indian pharma market, as per latest AIOCD report. Overall, the company is now ranked no. 1 based on share of prescriptions with 7 classes of specialists: psychiatrists, neurologists, cardiologists, ophthalmologists, orthopedicians, gastroenterologists and nephrologists.
Established in 1983, Sun Pharma is an international, integrated, speciality pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India, US and several other markets across the world. In India, the company is a leader in niche therapy areas of psychiatry, neurology, cardiology, diabetology, gastroenterology, orthopedics and ophthalmology. The company has strong skills in product development, process chemistry, and manufacturing of complex API, as well as dosage forms.